Citadel Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $255M | Buy |
4,512,634
+3,147,943
| +231% | +$184M | 0.04% | 355 |
|
|
2025
Q4 | $81.1M | Buy |
1,364,691
+966,844
| +243% | +$52.6M | 0.01% | 1008 |
|
|
2025
Q3 | $21.5M | Buy |
397,847
+62,827
| +19% | +$3.59M | ﹤0.01% | 2238 |
|
|
2025
Q2 | $18.4M | Sell |
335,020
-1,260,038
| -79% | -$74.2M | ﹤0.01% | 2242 |
|
|
2025
Q1 | $113M | Buy |
1,595,058
+1,207,445
| +312% | +$81.2M | 0.02% | 627 |
|
|
2024
Q4 | $25.5M | Sell |
387,613
-816,784
| -68% | -$54.7M | ﹤0.01% | 1905 |
|
|
2024
Q3 | $84.7M | Buy |
1,204,397
+646,545
| +116% | +$54M | 0.02% | 808 |
|
|
2024
Q2 | $45.9M | Sell |
557,852
-1,417,706
| -72% | -$118M | 0.01% | 1215 |
|
|
2024
Q1 | $173M | Buy |
1,975,558
+1,620,613
| +457% | +$145M | 0.03% | 429 |
|
|
2023
Q4 | $34.2M | Buy |
354,945
+213,413
| +151% | +$18.9M | 0.01% | 1494 |
|
|
2023
Q3 | $12.5M | Sell |
141,532
-340,807
| -71% | -$30.3M | ﹤0.01% | 2402 |
|
|
2023
Q2 | $41.8M | Buy |
482,339
+358,771
| +290% | +$33.8M | 0.01% | 1197 |
|
|
2023
Q1 | $12M | Sell |
123,568
-6,933
| -5% | -$719K | ﹤0.01% | 2561 |
|
|
2022
Q4 | $13.5M | Sell |
130,501
-871,813
| -87% | -$81.8M | ﹤0.01% | 2417 |
|
|
2022
Q3 | $85M | Sell |
1,002,314
-150,761
| -13% | -$13.4M | 0.02% | 692 |
|
|
2022
Q2 | $95.6M | Sell |
1,153,075
-937,328
| -45% | -$74.6M | 0.02% | 598 |
|
|
2022
Q1 | $161M | Buy |
2,090,403
+732,488
| +54% | +$61.3M | 0.03% | 437 |
|
|
2021
Q4 | $120M | Buy |
1,357,915
+1,308,848
| +2,667% | +$108M | 0.02% | 563 |
|
|
2021
Q3 | $3.79M | Sell |
49,067
-911,095
| -95% | -$71.9M | ﹤0.01% | 4866 |
|
|
2021
Q2 | $80.1M | Sell |
960,162
-673,518
| -41% | -$53.4M | 0.02% | 803 |
|
|
2021
Q1 | $123M | Sell |
1,633,680
-1,361,590
| -45% | -$111M | 0.03% | 487 |
|
|
2020
Q4 | $263M | Buy |
2,995,270
+517,914
| +21% | +$41.1M | 0.07% | 182 |
|
|
2020
Q3 | $188M | Buy |
2,477,356
+2,222,384
| +872% | +$225M | 0.05% | 213 |
|
|
2020
Q2 | $31.4M | Sell |
254,972
-4,355
| -2% | -$433K | 0.01% | 1126 |
|
|
2020
Q1 | $21.9M | Sell |
259,327
-1,780,826
| -87% | -$153M | 0.01% | 1171 |
|
|
2019
Q4 | $172M | Buy |
2,040,153
+282,923
| +16% | +$21.4M | 0.07% | 209 |
|
|
2019
Q3 | $118M | Buy |
1,757,230
+587,616
| +50% | +$45.3M | 0.06% | 331 |
|
|
2019
Q2 | $100M | Buy |
1,169,614
+40,966
| +4% | +$3.5M | 0.05% | 396 |
|
|
2019
Q1 | $100M | Sell |
1,128,648
-229,037
| -17% | -$21.2M | 0.05% | 363 |
|
|
2018
Q4 | $116M | Sell |
1,357,685
-1,101,023
| -45% | -$105M | 0.06% | 278 |
|
|
2018
Q3 | $238M | Buy |
2,458,708
+625,303
| +34% | +$62.4M | 0.11% | 135 |
|
|
2018
Q2 | $173M | Buy |
1,833,405
+457,896
| +33% | +$40.1M | 0.09% | 190 |
|
|
2018
Q1 | $112M | Sell |
1,375,509
-939,566
| -41% | -$80.6M | 0.06% | 284 |
|
|
2017
Q4 | $206M | Buy |
2,315,075
+671,639
| +41% | +$58.4M | 0.13% | 133 |
|
|
2017
Q3 | $153M | Buy |
1,643,436
+1,401,415
| +579% | +$124M | 0.12% | 139 |
|
|
2017
Q2 | $22M | Sell |
242,021
-224,884
| -48% | -$20.5M | 0.02% | 945 |
|
|
2017
Q1 | $41M | Sell |
466,905
-233,832
| -33% | -$20.8M | 0.04% | 545 |
|
|
2016
Q4 | $58M | Sell |
700,737
-272,548
| -28% | -$23.4M | 0.06% | 326 |
|
|
2016
Q3 | $90M | Sell |
973,285
-680,698
| -41% | -$64.1M | 0.09% | 190 |
|
|
2016
Q2 | $129M | Sell |
1,653,983
-540,892
| -25% | -$46M | 0.14% | 99 |
|
|
2016
Q1 | $181M | Buy |
2,194,875
+2,121,458
| +2,890% | +$173M | 0.23% | 52 |
|
|
2015
Q4 | $7.69M | Sell |
73,417
-353,165
| -83% | -$36.9M | 0.01% | 1466 |
|
|
2015
Q3 | $44.9M | Sell |
426,582
-153,235
| -26% | -$20.5M | 0.04% | 485 |
|
|
2015
Q2 | $79.3M | Sell |
579,817
-385,389
| -40% | -$47.8M | 0.07% | 306 |
|
|
2015
Q1 | $120M | Sell |
965,206
-492,997
| -34% | -$52.2M | 0.11% | 179 |
|
|
2014
Q4 | $132M | Buy |
1,458,203
+256,311
| +21% | +$21.3M | 0.13% | 125 |
|
|
2014
Q3 | $86.7M | Buy |
1,201,892
+634,138
| +112% | +$41.7M | 0.09% | 216 |
|
|
2014
Q2 | $35.3M | Sell |
567,754
-69,792
| -11% | -$4.22M | 0.04% | 518 |
|
|
2014
Q1 | $43.5M | Buy |
637,546
+89,804
| +16% | +$6.62M | 0.05% | 451 |
|
|
2013
Q4 | $38.5M | Buy |
547,742
+80,715
| +17% | +$5.48M | 0.05% | 461 |
|
|
2013
Q3 | $33.7M | Sell |
467,027
-419,963
| -47% | -$27.9M | 0.05% | 477 |
|
|
2013
Q2 | $49.5M | Buy |
+886,990
| New | +$55.3M | 0.09% | 264 |
|
Other funds holding BMRN
VCM
VPM
Citadel Advisors's BMRN Position: Q1 2026 in Review
Citadel Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 231% in Q1 2026, buying an estimated $184M and bringing the position to 4,512,634 shares worth $255M. The position accounts for 0.04% of the portfolio, ranked #355.
Citadel Advisors first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $263M in Q4 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Citadel Advisors held 4,512,634 shares of BioMarin Pharmaceuticals worth $255M as of Q1 2026.
- Citadel Advisors bought 3,147,943 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $184M.
- BioMarin Pharmaceuticals made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #355 holding.
- Citadel Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citadel Advisors's BioMarin Pharmaceuticals position peaked at $263M in Q4 2020.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.